Evidence map›Paper›PMID 29687624›Full record

ArticleEnvironmental microbiology reports2018

Environmental reservoirs for exoS+ and exoU+ strains of Pseudomonas aeruginosa.

Victoria Rutherford, Kelly Yom, Egon A Ozer, Olivia Pura, Ami Hughes, Katherine R Murphy, Laura Cudzilo, David Mitchell, Alan R Hauser

Abstract read
In one paragraph

Article in Environmental microbiology reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed.

  1. Article
  2. Prevalence and Antimicrobial Resistance ofInfectious disease reports · 2026
    Article
  3. mSystems · 2026
    Article
  4. Article
  5. Article
  6. Trends in Antimicrobial Resistance ofPharmaceuticals (Basel, Switzerland) · 2025
    Article
  7. Article
  8. Article
  9. Review
  10. Urinary tract infections and catheter-associated urinary tract infections caused byMicrobiology and molecular biology reviews : MMBR · 2024
    Review
  11. Review
  12. Article
  13. Article
  14. Microorganisms · 2023
    Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Role of Host and Bacterial Lipids inFrontiers in immunology · 2022
    Review
  20. A panel of diverseJAC-antimicrobial resistance · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Victoria RutherfordDepartment of Microbiology-Immunology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Kelly YomDepartment of Microbiology-Immunology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Egon A OzerDepartment of Medicine Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Olivia PuraDepartment of Microbiology-Immunology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Ami HughesDepartment of Microbiology-Immunology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Katherine R MurphyDepartment of Microbiology-Immunology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Laura CudziloDepartment of Biology, St. John's University, Collegeville, MN, USA.
David MitchellDepartment of Biology, St. John's University, Collegeville, MN, USA.
Alan R HauserDepartment of Microbiology-Immunology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.ORCID 0000-0003-4596-7939

Funding

Technology CoreU19AI135964 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI ALAN R HAUSER · 2018 to 2026
$24.7M
Population Analysis of Pseudomonas aeruginosa VirulenceR01AI118257 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI HAUSER, ALAN R · 2016 to 2025
$4.9M
Mechanistic Studies of Patatin-like ToxinsR01AI053674 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI HAUSER, ALAN R · 2003 to 2017
$4.3M
Patient-Oriented Research on Pseudomonas aeruginosaK24AI104831 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI HAUSER, ALAN R · 2013 to 2024
$1.2M
NIAID NIH HHS K24 AI104831NIAID NIH HHS R01 AI053674NIAID NIH HHS R01 AI118257NIAID NIH HHS U19 AI135964
6 · The paper itself

Abstract

Pseudomonas aeruginosa uses its type III secretion system to inject the effector proteins ExoS and ExoU into eukaryotic cells, which subverts these cells to the bacterium's advantage and contributes to severe infections. We studied the environmental reservoirs of exoS+ and exoU+ strains of P. aeruginosa by collecting water, soil, moist substrates and plant samples from environments in the Chicago region and neighbouring states. Whole-genome sequencing was used to determine the phylogeny and type III secretion system genotypes of 120 environmental isolates. No correlation existed between geographic separation of isolates and their genetic relatedness, which confirmed previous findings of both high genetic diversity within a single site and the widespread distribution of P. aeruginosa clonal complexes. After excluding clonal isolates cultured from the same samples, 74 exoS+ isolates and 16 exoU+ isolates remained. Of the exoS+ isolates, 41 (55%) were from natural environmental sites and 33 (45%) were from man-made sites. Of the exoU+ isolates, only 3 (19%) were from natural environmental sites and 13 (81%) were from man-made sites (p < 0.05). These findings suggest that man-made water systems may be a reservoir from which patients acquire exoU+ P. aeruginosa strains.

Indexed as

Environmental MicrobiologyADP Ribose TransferasesBacterial ProteinsBacterial ToxinsChicagoGenetic VariationGenome, BacterialGenotypePhylogenyPseudomonas aeruginosaSequence Analysis, DNAType III Secretion SystemsADP Ribose TransferasesBacterial ProteinsBacterial Toxinsexoenzyme Spseudomonas exoprotein A protein, Pseudomonas aeruginosaType III Secretion Systems

Identifiers

PMID29687624
PMCPMC6108916

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.